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Each patient’s immune defenses play a major role in mitigating the impact (ie, morbidity and mortality) of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Vitamin
D is an important modulator of the immune system. Although serum 25-hydroxyvitamin D levels can be raised through diet
or supplements, most vitamin D in the body is the result of dermal synthesis from ultraviolet radiation. The production of
vitamin D in the skin, however, can be limited by latitude, skin-covering clothes, the use of sunblock, and skin pigmentation.
Vitamin D deficiency affects a high percentage of the world population. Serum 25-hydroxyvitamin D levels are suboptimal,
not only in specific risk groups but also in adults from many countries. Low vitamin D levels, therefore, represent a risk factor
for several different pathologies, including SAR-CoV-2. This study used an ecological design to assess the association between
vitamin D deficiency and COVID-19 incidence, complications, and mortality across 46 countries. All data were obtained
from published sources. The results of the study suggest an association at the population level between the prevalence of
vitamin D deficiency and the risk of being infected with COVID-19, severity of the disease, and risk of dying from it.
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Introduction
Each patient’s immune defenses play a major role inmitigating the impact (ie, morbidity and mortality)
of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the virus responsible for coronavirus disease 2019
(COVID-19).1 The patient’s immune-inflammatory re-
sponse is notably involved in the physiopathogenesis of this
viral disease, in which multiple cellular pathways and com-
ponents, including vitamin D,2 are implicated. Vitamin D is
an important modulator of the immune system.3 Specifically,
vitamin D exerts anti-infectious and immunomodulatory
action by improving intercellular barriers by stimulating in-
nate immunity, as well as by modulating adaptive immunity.
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Vitamin D reduces the production of inflammatory cyto-
kines, such as interleukin-2 and interferon-gamma. Fur-
thermore, in close connection, multiple pleiotropic effects
have been demonstrated on the actions of vitamin D at the
anti-inflammatory and immunomodulatory level with posi-
tive results in studies with influenza, coronavirus, and other
respiratory infections.4
Vitamin D levels, measured by serum 25-hydroxyvitamin
D [25(OH)D] concentration, increase after exposure of skin
to sunlight and decrease during the ‘‘dark months’’ of the year
(when skin is usually covered), fluctuating from 30% to 50%
in some cases.5-7 Although 25(OH)D levels can be raised
through diet or supplements, most vitamin D in the body
(between 50% and 90%) is the result of dermal synthesis
from ultraviolet radiation. The production of vitamin D in
the skin, however, can be limited by latitude, skin-covering
clothes, the use of sunblock, and skin pigmentation.8
In addition to its nonenzymatic synthesis, vitamin D
is enzymatically converted into its active form—1,25-
dihydroxyvitamin D [1,25(OH)2D]—in the kidneys and
liver mainly, although it is also produced in other organs,
tissues, and cells, such as prostate, placenta, lungs, brain, and
immune cells.9,10 Vitamin D is a steroid hormone, and 1,25-
(OH)2D is the ligand for the vitamin D receptor. Cells
lacking the vitamin D receptor are the exception rather than
the rule, and this widespread distribution underlies the po-
tential myriad of physiological actions for vitamin D.11
International consensus on the definition of vitamin D
deficiency is lacking; however, it is accepted that a serum
25(OH)D level of 20 nanograms per milliliter (ng/mL)* is
the threshold of sufficiency for 97.5% of the population in
terms of bone health.5 Vitamin D deficiency is highly
prevalent and affects a high percentage of the world pop-
ulation.12 Serum 25(OH)D levels are not only suboptimal
in specific risk groups but also in adults from many
countries—especially in the Middle East and Asia, where
vitamin D deficiency in adults is highly prevalent.13 The
lack of sufficient levels of serum vitamin D in communities
has shown greater susceptibility to a broad spectrum of
diseases, in addition to the classically described bone dis-
orders.14,15 It has been found that low vitamin D levels
represent a risk factor for several different pathologies,
such as autoimmune, neurodegenerative, and cardiovas-
cular diseases, as well as diabetes, osteoporosis, cancer, and
infectious diseases such as viral infections.12 Accordingly,
vitamin D has been associated with the current pandemic
because of its potential role in reducing the risk of SAR-
CoV-2 infection.16,17
Of special interest, vitamin D has important antiviral
properties, including the induction of cathelicidin and b2-
defensins synthesis.18 Cathelicidin and b2-defensins exert
significant antibiotic and antiviral effects. These pluripo-
tent peptides have a crucial role in innate immunity, and
their regulation is abnormal in hypovitaminosis D.
This study aimed to assess the association of vitamin D
deficiency on COVID-19 incidence, complications, and
mortality in 46 countries.
Methods
Design
This study used an ecological design to correlate COVID-19
infection risk and outcome variables and vitamin D deficiency
levels at the country level. All data were obtained from online
published sources. Since all of the data were anonymized and
publicly available, no ethical approval was sought.
Vitamin D Deficiency
Vitamin D deficiency was defined as a 25(OH)D serum
level of less than 20 ng/mL.5,19 Data for national prevalence
estimates of vitamin D deficiency were obtained from
population studies reported elsewhere,5,13,20 and are ex-
pressed as the estimated percentage of population with vi-
tamin D deficiency. If more than 1 estimate was found, the
more conservative (ie, the lower prevalence) and those
corresponding to the broadest population representation
(ie, the majority of population subgroups) were used.
COVID-19 Cases, Tests,
and Mortality
Data on the number of COVID-19 cases, number of tests
performed, number of deaths from COVID-19, and pop-
ulation were obtained from Worldometer.21 This website
collects and publish information from country’s official
channels. We used data as published on July 4, 2020. We
also obtained population data from this website to estimate
the population incidence of COVID-19 infection and the
population COVID-19 death rates.
Cases are reported as the cumulative number of indi-
viduals who tested positive for COVID-19 with a con-
firmed laboratory result and as rates per millions of people.
Tests are reported as the cumulative number of diagnostic
tests performed in a given country and as the number of
tests per millions of people. Mortality is reported as the
cumulative number of COVID-19 deaths and the rate per
millions of people. All deaths for every country are counted
in the rate, from the inception of each country’s first case.
Gross Domestic Product
Data on national gross domestic product (GDP) were ob-
tained from the World Bank’s DataBank. GDP for the year
2019 (in billions of US dollars) were used for analysis.22
*Serum 25(OH)D levels are also measured using nanomoles per
liter. The vitamin D deficiency threshold of 20 ng/mL is
equalivent to 50 nmol/L.
















































All data were extracted by 2 researchers to a worksheet
designed ad hoc. All data were extracted as published from
the aforementioned sources without further modifications.
All discrepancies were resolved by consensus. Only coun-
tries with available data for vitamin D status were included
(data for COVID-19 indicators and GDP were available
for all countries). After extraction, the case fatality ratio was
computed as the cumulative number of deaths per cumu-
lative number of cases, and the positivity ratio was com-
puted as the cumulative number of cases per cumulative
number of tests performed.
Statistical Analysis
Descriptive statistics were expressed as medians and in-
terquartile ranges (IQR). Comparisons across vitamins D
deficiency quintiles were conducted using the Kruskal-
Wallis test. The correlation between COVID-19 inci-
dence, positivity ratio, case fatality ratio, and death rate
were evaluated using Spearman’s correlation coefficient.
Furthermore, scatterplots with nonlinear regression lines
(ie, local regression) were constructed to present correla-
tion analysis.
To assess the association between COVID-19 indicators
and vitamin D deficiency, multivariate Poisson regression
models were constructed. Quintiles of vitamin D deficiency
at the population level were included as independent vari-
ables, and COVID-19 indicators as dependent variables.
All models were adjusted for GDP using log transforma-
tion. Results are reported as incidence rate ratios (IRR) with
their corresponding 95% confidence intervals. All tests were
2-tailed and a P value of less than .05 is considered statis-
tically significant. All analyses were conducted with R: A
Language and Environment for Statistical Computing,
version 4.0 for MacOS (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Overall, 46 countries with complete data were included in
the analysis. Table 1 presents a summary of COVID-19
and GDP indicators by quintiles of vitamin D deficiency.
The overall median percentage of vitamin D deficiency was
49.0 (IQR 26.8 to 56.6)—from 13.0 (IQR 7.5 to 17.0) in
the first quintile to 65.0 (IQR 60.0 to 68.9) in the fifth
quintile.
The overall median number of COVID-19 cases was
37,900 (IQR 4,400 to 153,600), with a median incidence
rate of 2,221.5 (IQR 330.2 to 4,145.2) cases. The median
number of COVID-19 deaths was 900 (IQR 100 to 8,700),
with a death rate of 53.0 (IQR 8.0 to 231.0). The median
case fatality ratio was 4.1 (IQR 1.4 to 6.1). The median test
rate was 46,000 (IQR 20,000 to 106,000) and the positivity
rate was 3.6% (IQR 1.1 to 7.3).
Vitamin D Deficiency
and COVID-19 Incidence
There was a positive and statistically significant correlation
between the incidence of COVID-19 infection and vitamin
D deficiency (R = 0.39; P = .0075) (Figure 1). Figure 2 and
Table 2 show the results of Poisson regression models.
Incidence rate ratios were positively associated with quin-
tiles of vitamin D deficiency.
Vitamin D Deficiency
and COVID-19 Positivity
There was a positive correlation (R = 0.36; P = .016)
between vitamin D deficiency and the positivity ratio
(Figure 1). In Poisson regression models (adjusted for
GDP), the association between the positivity ratio and vi-
tamin D deficiency was evident and the relationships were
strongest for the second quintile (IRR 2.01; 95% CI, 1.34
to 3.06; P = .001), the fourth quintile (IRR 1.72; 95% CI,
1.15 to 2.62; P < .010) and the fifth quintile (IRR 2.17;
95% CI, 1.48 to 3.26; P < .001) (Figure 2, Table 2).
Vitamin D Deficiency and Case
Fatality Ratio and Death Rate
There were positive and statistically significant correlations
between vitamin D deficiency and the case fatality ratio
(R = 0.40; P = .007) and death rate (R = 0.38; P = .011)
(Figure 1). For the case fatality ratio, the IRR in the fifth
quintile was more than double the IRR in the first quintile,
after adjusting for GDP. The death rate was higher in the
third, fourth, and fifth quintiles (Figure 2, Table 2).
Discussion
The results of the present study suggest an association at the
population level between the prevalence of vitamin D defi-
ciency and the risk of being infected with COVID-19, se-
verity of the disease, and risk of dying from it. These
associations were consistent in both correlation analyses and
Poisson regression models adjusted for GDP (the indicator for
socioeconomic level). This study extends those observations
by quantifying the association between incidence and severity
of COVID-19 and documenting the association with the case
fatality ratio. A strength of this study is the inclusion and
analysis of information from 46 countries around the world.
A 2010 study showed that people with a mean serum
25(OH)D concentration level of more than 38 ng/mL—
over a period of 4 to 5 months during fall and winter—had
less than half the incidence rate of acute viral respiratory
infections seen in those with lower concentrations.23 An-
other ecological study found that communities exposed to
higher solar ultraviolet type B radiation doses—both in
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summer and in winter—had a significantly lower case fa-
tality rate during the 1918-1919 influenza pandemic in the
United States.24 One study in South Korea found that a
serum 25(OH)D concentration of more than 20 ng/mL
was associated with an adjusted odds ratio for mortality of
0.94 (95% CI, 0.90 to 0.99) for those who developed
community-acquired pneumonia.25
Evidence suggests that vitamin D could play a protective
role against COVID-19 infection. A 2020 review of evi-
dence26 included the following as evidence supporting the
protective role of vitamin D: the occurrence of outbreaks
during the winter (when serum levels of vitamin D are
lowest), the low number of cases observed in the southern
hemisphere near the end of summer, the association
Figure 2. Poisson regression models assessing the association between COVID-19 indicators and vitamin D deficiency quintiles. a = P
value < .05; b = P value < .01; c = P value < .001. Abbreviations: IRR, incidence rate ratio; Q, quintile.
Figure 1. Correlation between vitamin D deficiency and COVID-19 indicators.
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between vitamin D deficiency and the development of
acute respiratory distress syndrome, and that mortality rates
increase in older adults and in patients with chronic diseases
(both age and chronic disease comorbidity are associated
with reduced serum 25(OH)D concentrations). It has been
suggested that a strong correlation exists between latitude,
which directly influences a person’s exposure to sunlight,
and mortality following COVID-19 infection.27,28 Low
mortality rates observed in Nordic countries are exceptions
that could be explained by strong supplementation and
food fortification with vitamin D carried out in these
countries.29 Epidemiological studies in Europe and the
United States have also suggested an inverse relationship
between vitamin D levels and COVID-19 risk.30,31 Vita-
min D supplementation has consistently been considered
useful in the treatment of COVID-19 infection.32
Furthermore, a 2020 study determined that vitamin D
may interfere with the functionality of 70% of SARS-CoV-
2 proteins through alteration of the expression of 25% of
human genes encoding protein targets of SARS-CoV-2. 33
Deficiency in vitamin D would, therefore, contribute to
susceptibility to infection and morbidity and mortality due
to COVID-19. It has also been reported that one of the
main defenses against uncontrolled inflammation, espe-
cially of viral origin, is represented by regulatory T cells.
Many patients with COVID-19 have been found to have
reduced levels of regulatory T cells, which may be increased
by supplementation with vitamin D.34
Limitations
This study has several limitations that are important to
consider when interpreting the results. Because it is an
ecological study, the results do not mean that individuals
with vitamin D deficiency are at increased risk of COVID-
19 infection and mortality (this would be an ecological
fallacy). However, evidence from observational studies
suggest that the relationship between COVID-19 risk and
mortality remains at the level of the individual participants.
Because the number of countries included in our analysis
was determined by the countries with available population
estimates for 25(OH)D deficiency identified in our search,
we acknowledge that the inclusion of all countries with
reported COVID-19 data could change the results. How-
ever, as discussed previously, observations from other
studies with different designs are consistent with our results.
Conclusion
The results of the present study suggest that vitamin D
deficiency as associated with an increased risk of COVID-
19 infection and mortality across a wide range of countries.
Since the accumulating body of evidence strongly suggests
the risks of vitamin D deficiency and the benefits of vitamin
D supplementation, there is an urgent need for evidence
from well-designed clinical trials evaluating vitamin D
supplementation for the prevention and treatment of
COVID-19 in different settings.
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